Reitan Colleen F's Form 4 filing
Alnylam Pharmaceuticals, Inc. (ALNY) · filed Sep 11, 2025
- Accession no.
- 0001735276-25-000097
- Filed
- Sep 11, 2025
- Trade date
- Sep 9, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 17 non-derivative transactions and 1 derivative transaction. Open-market sales total $8.42M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Reitan Colleen FCIK 0001740730 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2025 | Common Stock | MOption exerciseAcquired | +18,000 | $100.65 | +$1,811,700 | 18,775 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −1,645 | $457.44 | −$752,488.8 | 17,130 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −1,888 | $458.86 | −$866,327.68 | 15,242 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −1,403 | $459.73 | −$645,001.19 | 13,839 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −473 | $460.71 | −$217,915.83 | 13,366 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −2,290 | $461.92 | −$1,057,796.8 | 11,076 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −1,652 | $463.00 | −$764,876 | 9,424 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −799 | $464.36 | −$371,023.64 | 8,625 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −222 | $471.25 | −$104,617.5 | 8,403 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −823 | $472.82 | −$389,130.86 | 7,580 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −838 | $474.22 | −$397,396.36 | 6,742 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −951 | $474.85 | −$451,582.35 | 5,791 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −972 | $476.31 | −$462,973.32 | 4,819 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −1,183 | $477.47 | −$564,847.01 | 3,636 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −1,450 | $478.67 | −$694,071.5 | 2,186 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −1,386 | $479.55 | −$664,656.3 | 800 | Direct | |
| Sep 9, 2025 | Common Stock | SSaleDisposed | −25 | $480.98 | −$12,024.5 | 775 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2025 | Common Stock | MOption exerciseDisposed | −18,000 | $0.00 | $0 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.